Allogene Therapeutics
ALLO
165 hedge funds and large institutions have $2.26B invested in Allogene Therapeutics in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 71 increasing their positions, 44 reducing their positions, and 19 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 44
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
21% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 19
2.51% more ownership
Funds ownership: 61.2% → 63.72% (+2.5%)
2% more funds holding
Funds holding: 162 → 165 (+3)
2% less call options, than puts
Call options by funds: $3.15M | Put options by funds: $3.23M
30% less capital invested
Capital invested by funds: $3.21B → $2.26B (-$957M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Primecap Management
Pasadena,
California
|
+$40.4M |
| 2 |
ROTUOC
Regents of the University of California
Oakland,
California
|
+$29.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$26.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$21.3M |
| 5 |
Goldman Sachs
New York
|
+$17.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.9M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$17M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$12.4M |
| 4 |
Capital World Investors
Los Angeles,
California
|
-$9.58M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$8.46M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AL
176
Aspiriant LLC
Los Angeles,
California
| – | -$253K | -6,700 | Closed |
|
177
D.E. Shaw & Co
New York
| – | -$244K | -6,459 | Closed |
|
|
IMRF
178
Illinois Municipal Retirement Fund
Oak Brook,
Illinois
| – | -$98K | -2,598 | Closed |
|
|
FHA
179
Flagship Harbor Advisors
Boston,
Massachusetts
| – | -$7K | -203 | Closed |
|
|
GT
180
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$5K | -150 | Closed |
|
|
CG
181
Cutler Group
San Francisco,
California
| – | -$3K | -100 | Closed |
|
|
S
182
SignatureFD
Atlanta,
Georgia
| – | -$2K | -42 | Closed |
|
|
NSIM
183
North Star Investment Management
Chicago,
Illinois
| – | +$33 | +1 | New |
|
ALLO Hedge Fund Activity: Q4 2020 in Review
165 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q4 2020, worth a combined $2.26B — down 30% from $3.21B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ALLO positions and 19 closed out — a net gain of 4 holders — while 71 added to existing stakes and 44 trimmed.
The largest buyer was Primecap Management, opening a new position worth an estimated $40.4M. The largest seller was Fidelity Investments, cutting an estimated $23.9M.
- 165 institutional investors held Allogene Therapeutics (ALLO) as of Q4 2020, up from 162 in Q3 2020.
- Funds reported $2.26B of Allogene Therapeutics stock for Q4 2020, down 30% quarter-over-quarter.
- 23 funds opened new Allogene Therapeutics positions in Q4 2020 and 19 closed out, a net change of +4 holders.
- The largest Allogene Therapeutics buyer in Q4 2020 was Primecap Management, an estimated $40.4M added.
- The largest Allogene Therapeutics seller in Q4 2020 was Fidelity Investments, an estimated $23.9M sold.
Based on aggregated 13F filings for Q4 2020.